1361383-92-7

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 1667-11-4 biphenyl-4-methylchloride 
• 636589-63-4 4-{{2-[4-(trifluoromethyl)phenyl]-4-methylthiazol-5-yl}methylthio}-2-methylphenol 
• 317318-97-1 5-(chloromethyl)-4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole 
• 2567-29-5 p-phenylbenzyl bromide 

Downstream Products

• 1361383-93-8 C₃₂H₂₆F₃NOS₂ 
• 1361383-94-9 C₃₆H₃₂F₃NO₃S₂ 
• 1361383-95-0 2-(4-(2-(biphenyl-4-yl)-1-(4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)ethylthio)-2-methylphenoxy)acetic acid 

Relevant academic research and scientific papers

USE OF THE FETAL REPROGRAMMING OF A PPAR AGONIST

The present invention relates to a novel use of a PPAR δ agonist, and more particularly, to a fetal reprogramming effect of a PPAR δ agonist. According to the present invention, a PPAR δ agonist adjusts calcium ion during embryo genesis and a early fetal development period to increase slow muscle fiber and to thus improve muscle endurance, thereby improving lipid and glucose metabolism and reprogramming the metabolism of the entire body, thus preventing/inhibiting the occurrence of metabolic diseases, such as obesity and diabetes in an adult body caused by a high-fat diet and a lack of exercise, and improving memory for an adult. In addition, fetal reprogramming using a PPAR δ agonist prevents/inhibits the occurrence of diabetes in a mouse model for diabetes. Therefore, the PPAR δ agonist may be used in a pharmaceutical composition for enhancing the endurance of a human and an animal by embryonic/fetal reprogramming, preventing/inhibiting metabolic diseases such as obesity, diabetes, arteriosclerosis and fatty liver, and enhancing memory. The PPAR δ agonist may also be used in a nutritional supplement for pregnant women, in food additives, in a functional food supplement or functional beverage composition, in pharmaceutical compositions for animals, in an endurance enhancer for animals, in dry milk and baby formula compositions, in an animal feed composition, etc.

Discovery, design and synthesis of Y-shaped peroxisome proliferator- activated receptor δ agonists as potent anti-obesity agents in vivo

We have discovered and demonstrated the in vitro and in vivo PPARδ-selective activity of novel Y-shaped agonists. These compounds activated hPPARδ with EC50 values between 1 and 523 nM. Surprisingly, compounds 10a, 11d, 11e and 11f were the mos